Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 12,470 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,470 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $41.24, for a total value of $514,262.80. Following the completion of the sale, the chief operating officer owned 22,714 shares of the company’s stock, valued at $936,725.36. The trade was a 35.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Eben Tessari also recently made the following trade(s):

• On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $37.67, for a total value of $465,902.56.
• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $38.33, for a total value of $1,609,860.00.
• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $36.46, for a total value of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.52, for a total value of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total value of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.

Kiniksa Pharmaceuticals International Stock Up 2.1%

NASDAQ:KNSA traded up $0.88 during mid-day trading on Wednesday, reaching $42.16. The company’s stock had a trading volume of 361,832 shares, compared to its average volume of 618,670. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $42.30. The stock has a fifty day moving average of $38.13 and a 200-day moving average of $32.63. The firm has a market capitalization of $3.20 billion, a PE ratio of 93.69 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the prior year, the firm posted ($0.18) EPS. The company’s revenue for the quarter was up 61.2% compared to the same quarter last year. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KNSA. Nuveen LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $16,992,000. Arrowstreet Capital Limited Partnership acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $20,349,000. Qube Research & Technologies Ltd raised its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock worth $22,961,000 after buying an additional 651,700 shares during the period. Finally, Rubric Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after buying an additional 526,567 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on KNSA. TD Cowen began coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a “buy” rating and a $60.00 target price for the company. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $52.00.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.